Paraoxonase 1 gene polymorphisms do not influence the response to treatment in Alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 32, Issue 1, 2011, Pages 26-31

  Klimkowicz Mrowiec, A ^a   Marona, M ^b   Spisak, K ^b   Jagiella, J ^b   Wolkow, P ^a   Szczudlik, A ^a   Slowik, A ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b UNIVERSITY HOSPITAL IN KRAKOW   (Poland)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's disease; Paraoxonases; Polymorphisms; Response to treatment

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; DONEPEZIL; RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; ARTICLE; FEMALE; GENE EXPRESSION; GENE LOCUS; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

AGED; ALZHEIMER DISEASE; APOLIPOPROTEINS E; ARYLDIALKYLPHOSPHATASE; CHOLINESTERASE INHIBITORS; DNA; FEMALE; HAPLOTYPES; HETEROZYGOTE; HUMANS; INDANS; MALE; NEUROPSYCHOLOGICAL TESTS; PHENYLCARBAMATES; PIPERIDINES; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 79961113681     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000330343     Document Type: Article

References (23)

1. Hansen RA, Gartlehner G, Lohr KN, Kaufer DI: Functional outcomes of drug treatment in Alzheimer's disease: a systematic review and meta-analysis. Drugs Aging 2007;24:155-167. (Pubitemid 46327574)
2. Bryk B, BenMoyal-Segal L, Podoly E, Livnah O, Eisenkraft A, Luria S, Cohen A, Yehezkelli Y, Hourvitz A, Soreq H: Inherited and acquired interactions between ACHE and PON1 polymorphisms modulate plasma acetylcholinesterase and paraoxonase activities. J Neurochem 2005;92:1216-1227. (Pubitemid 40344311)
3. Costa LG, Cole TB, Vitalone A, Furlong CE: Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. Clin Chim Acta 2005;352:37-47. (Pubitemid 40093856)
4. Adkins S, Gan KN, Mody M, La Du BN: Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993;52:598-608. (Pubitemid 23311330)
5. Draganov DI, La Du BN: Pharmacogenetics of paraoxonases: a brief review. Naunyn Schmiedebergs Arch Pharmacol 2004;369:78-88. (Pubitemid 38161225)
6. Brophy VH, Hastings MD, Clendenning JB, Richter RJ, Jarvik GP, Furlong CE: Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 2001;11:77-84. (Pubitemid 32108664)
7. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE: Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet 2001;68:1428-1436. (Pubitemid 32510618)
8. Leduc V, Poirier J: Polymorphisms at the paraoxonase 1 L55M and Q192R loci affect the pathophysiology of Alzheimer's disease: emphasis on the cholinergic system and beta-amyloid levels. Neurodegener Dis 2008;5:225-227. (Pubitemid 351347857)
9. Pola R, Flex A, Ciaburri M, Rovella E, Valiani A, Reali G, Silveri MC, Bernabei R: Responsiveness to cholinesterase inhibitors in Alzheimer's disease: a possible role for the 192 Q/R polymorphism of the PON-1 gene. Neurosci Lett 2005;15:338-341. (Pubitemid 40733648)
10. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadian EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force of Alzheimer's disease. Neurology 1984;34:939-944. (Pubitemid 14076461)
11. Klimkowicz-Mrowiec A, Slowik A, Krzywoszanski L, Herzog-Krzywoszanska R, Szczudlik A: Severity of explicit memory impairment due to Alzheimer's disease improves effectiveness of implicit learning. J Neurol 2008;20:234-240.
12. National Institute for health and Clinical Excellence: Response criteria. www.nice.org. uk.
13. Folstein MF, Folstein SE, McHugh PR: 'Mini Mental State': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
14. Sunderland T, Hill JL, Mellow AM, et al: Clock drawing in Alzheimer's disease: a novel measure of dementia severity. J Am Geriatr Soc 1989;37:725-729. (Pubitemid 19199790)
15. Lawton MP, Brody EM: Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-186.
16. Pilotto A, Franceschi M, D'Onofrio G, Bizzarro A, Mangialasche F, Cascavilla L, Paris F, Matera MG, Pilotto A, Daniele A, Mecocci P, Masullo C, Dallapiccola B, Seripa D: Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology 2009;8:761-767.
17. Babiloni C, Cassetta E, Dal Forno G, Del Percio C, Ferreri F, Ferri R, Lanuzza B, Miniussi C, Moretti DV, Nobili F, Pascual-Marqui RD, Rodriguez G, Luca Romani G, Salinari S, Zanetti O, Rossini PM: Donepezil effects on sources of cortical rhythms in mild Alzheimer's disease: responders versus non-responders. Neuroimage 2006;15:1650-1665.
18. Raschetti R, Maggini M, Sorrentino GC, Martini N, Caffari B, Vanacore N: A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease. Eur J Clin Pharmacol 2005;61:361-368. (Pubitemid 41569310)
19. Yoshida T, Ha-Kawa S, Yoshimura M, Nobuhara K, Kinoshita T, Sawada S: Effectiveness of treatment with donepezil hydrochloride and changes in regional cerebral blood flow in patients with Alzheimer's disease. Ann Nucl Med 2007;21:257-265. (Pubitemid 350104523)
20. Saumier D, Murtha S, Bergman H, Phillips N, Whitehead V, Chertkow H: Cognitive predictors of donepezil therapy response in Alzheimer disease. Dement Geriatr Cogn Disord 2007;24:28-35. (Pubitemid 46985288)
21. Eagger SA, Harvey RJ: Clinical heterogeneity: responders to cholinergic therapy. Alzheimer Dis Assoc Disord 1995;9:37-42.
22. Borroni B, Colciaghi F, Pastorino L, Archetti S, Corsini P, Cattabeni F, Di Luca M, Padovani A: ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral model. Eur Neuropsychopharmacol 2002;12:195-200. (Pubitemid 34464109)
23. Cacabelos R: Pharmacogenomics and therapeutic prospects in dementia. Eur Arch Psychiatry Clin Neurosci 2008;258:28-47. (Pubitemid 351424036)